Thu, Aug 28, 2014, 11:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

PolyMedix, Inc. Message Board

mulletman99 137 posts  |  Last Activity: Aug 20, 2014 10:17 PM Member since: Feb 1, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    10Q

    by mulletman99 Aug 19, 2014 12:11 PM
    mulletman99 mulletman99 Aug 20, 2014 10:17 PM Flag

    Also, in the last presentation the CEO gave, he said they are "almost finished" with the p2 CardioPET trial and will be analyzing data. and BFPET will start enrolling patients "any day now". They signed PPD as their CRO (VERY reputable CRO) back in May

  • Reply to

    10Q

    by mulletman99 Aug 19, 2014 12:11 PM
    mulletman99 mulletman99 Aug 20, 2014 10:12 PM Flag

    If you do that math, they just reported operating expenses of $1.2M for Q2. They had $100k at the end of Q2 and then raised $1.2M in cash through promissory notes in which most company execs took part. They get paid in stock and warrants with the next raise. Nice incentive for them and a nice non-diluitive financing for us.
    They basically just told us (without telling us), that the results will be this quarter.

    My guess is that they get the CardioPET results and partner it out, bringing in some nice cash to fund BFPET. If the pps doesnt increase enough to do it on its own, they will RS to get listed and offer stock to institutions at the same time to get exposure outside of Zacks SCR.

    All IMO.....think for yourselves!

  • mulletman99 by mulletman99 Aug 19, 2014 12:11 PM Flag

    10Q was released last Thursday. I didnt see anything in there that wasnt already known.
    Anyone?

    Low volume. I guess everyone is just waiting for the 2 impending announcements like I am?

    Getting close folks.

  • Yoohooooo wont let me post the link to the form D.

    3. Related Persons
    Last Name First Name Middle Name
    Spoor Johan (Thijs) M.
    Relationship: x Executive Officer x Director o Promoter


    Last Name First Name Middle Name
    Rhein Tamara
    Relationship: x Executive Officer o Director o Promoter


    Last Name First Name Middle Name
    Witoshkin Walter
    Relationship: o Executive Officer x Director o Promoter


    Last Name First Name Middle Name
    Conti Peter S.
    Relationship: o Executive Officer x Director o Promoter


    Last Name First Name Middle Name
    Atinsky Lawrence
    Relationship: o Executive Officer x Director o Promoter


    Last Name First Name Middle Name
    Pierro Joseph A.
    Relationship: o Executive Officer x Director o Promoter


    Last Name First Name Middle Name
    Sassine Andrew H.
    Relationship: o Executive Officer x Director o Promoter

  • mulletman99 mulletman99 Jul 28, 2014 9:50 PM Flag

    There hasn't been anything to talk about except for the fast that they were about to run out of money.
    Everyone should be tickled pink with this. Non diluitive financing. We now can surmise the reason for the delay in the start of BFPET phase2 and can also assume to expect an announcement shortly.

    This is basically a bridge loan to CardioPET results and gives the company time to get BFPET rolling.

  • mulletman99 mulletman99 Jul 28, 2014 4:42 PM Flag

    It will happen either when the money runs out (next year, like bocamp1 said), OR when the stock price is up and looks like a good time for a raise.(which could happen anytime....obviously).

    What is your point?

  • Reply to

    New 8K filed for product licensing

    by onebarkmill Jul 2, 2014 11:23 AM
    mulletman99 mulletman99 Jul 2, 2014 2:11 PM Flag

    Higher revenue potential for BFPET (according to the company) but CardioPET further along in development, so I'm not sure the market would care either way. Although the difference between the 2 wrt revenue projections is very small, while time to market could be significantly sooner for CardioPET.....hence my preference to partner out BFPET and get a revenue stream sooner.

  • Reply to

    New 8K filed for product licensing

    by onebarkmill Jul 2, 2014 11:23 AM
    mulletman99 mulletman99 Jul 2, 2014 11:50 AM Flag

    Key sentence:
    The Agreements were entered into primarily for the purpose of separating the Company's rights and obligations with respect to its different product development programs.

    My guess has always been.....they will partner off BFPET and use the money to fund CardioPET and go that alone. We will see, but it looks like this was a necessary step for financing of some sort.

  • Reply to

    Once Market Volatility Begins

    by investron Jun 11, 2014 10:46 PM
    mulletman99 mulletman99 Jun 12, 2014 11:02 AM Flag

    Once again Investron, your rhetoric does not jive with reality.

    Check the 6 month chart of ARWR vs TKMR. Over the last 6 months they have been hand-in-hand, so whatever (TECHNICALLY - CHART AND PPS WISE) you have to say about TKMR OBVIOUSLY applies to ARWR as well, based on the last 6 months of chart history.

    You must be VERY VERY bored with your life to spend so much time on the message board of a stock you dont even own. Get outside.....its nice out. Go hang with your family if you have one.....Im sure they arent THAT bad.

  • mulletman99 mulletman99 Jun 11, 2014 1:47 PM Flag

    The 1st post cut off the rest of the article, so here it is:

    Also.....after looking at the data posted by Zach's, it is obvious to me that "may be feasible" isnt anything to worry about. This data is WOW data, IMO.

    The compilation of the clinical data continues to reinforce our belief that CardioPET has potential to unseat the current standard imaging agents for coronary artery disease imaging.

    We cover FPMI with an Outperform rating and $2.15/share price target. See below for access to our most recent report on the company.

  • 06/11/2014
    By Brian Marckx, CFA

    OBB:FMPI

    Quantitative Phase II Data Provides Additional Support of CardioPET Utility

    FluoroPharma Inc. (OBB:FPMI) presented additional data from its ongoing phase II study of CardioPet during this week's Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) in St. Louis.

    As a reminder, CardioPET is being developed as a PET imaging agent to better diagnose acute and chronic coronary artery disease (CAD), among other potential indications. The Belgian-based phase II trial is an open label study designed to assess safety and performance of CardioPET compared to SPECT myocardial perfusion imaging (MPI) agents and angiography.

    In February of this year, at the SNMMI mid-Winter meeting held in Pam Springs, FPMI presented data on fifteen patients that demonstrated CardioPET enters the myocardium similar to the way of fatty acids, remains there long enough to allow for PET imaging but with rapid clearance, thereby minimizing patient exposure to imaging radiation. Image quality was considered excellent as was safety. The data indicated that CardioPET has the ability to attain high quality images very shortly after injection.

    The data presented this week at SNMMI in St. Louis reinforced the findings of the earlier data and provided a quantitative output of results. The quantitative output is presented in graphical form, showing both the rapid uptake and clearance (chart left) of CardioPET as well as how CardioPET can differentiate between normal and damaged tissue (chart right). While the excellent quality of CardioPET images provides a reliable qualitative measure for physicians in diagnosing CAD, this quantitative output demonstrated with the current data provides what is essentially a double-check of the images, offering physicians another tool with CardioPET PET imaging.

    ​ The compilation of the clinical data continues to reinforce our belief that CardioPET has potential to unseat the current standard ima

  • This was NOT the full phase 2 results.....THATS why the stock response is what it is.

    From their phase 2 design description:
    Secondary Objective:
    A secondary objective is to assess fatty acid uptake at rest and following stress.

    Check out the abstract for this presentation. It was for 5 people, 2 at rest and 3 after stress test.

    The phase 2 study has 30-40 patients total.....not 5.

    IMO, These results were very good.. Hospitals, doctors and insurance companies all like data driven decisions. This showed that they could quantify (put a number to or get data from) the blood flow into the heart tissue (perfusion) to help drive decisions on how to treat. This in combination with the higher resolution images shown in the interim analysis given in Feb point to a high market penetration if this is eventually approved.

    All IMO........think for yourselves.

  • Reply to

    Data presented June 10th - Tuesday - 2:45pm

    by mulletman99 Jun 9, 2014 11:09 AM
    mulletman99 mulletman99 Jun 10, 2014 10:50 AM Flag

    Yes. they released preliminary data back in February and the resolution looked fantastic compared to the current standard. No safety issues either. See write-ups by LifeTech or Zachs, or 1 of theIr presentations for the pictures and info presented. The BRIley presentation was the best, IMO.

  • http://interactive.snm.org/index.cfm?PageID=13072&A=11&B=106&E=667&PID=66757

  • Its official, there are MORE jobs now than at the peak prior to Bush destroying the economy. And Obama did this inspite of the GOP meeting in a backroom on inauguration day and agreeing to try to stop him from doing anything, and a record number of fillibusters.

  • mulletman99 mulletman99 Jun 6, 2014 11:21 AM Flag

    Yup. The right is SOOOOOOO upset that this guy apparently, speculatively, maybe abandoned his post. Yet, they didnt seem to care that Bush wasnt even man enough to go, and on top of that, DID, ABSOLUTELY, WITH 100% CERTAINTY, ABANDONED HIS POST at the Natl Guard.

    OH THE HYPOCRISY!!!!!

  • OH THE HYPOCRISY!!!!!!
    Where was the right's outrage over Bush not only getting a National Guard position b/c he was too much of a pu$$eeee to go to war, but then deserted his Natl Guard?

    "Try him and then hang him".....right board bagger????!!!!

    LMFAO!!!!

    I love seeing you still here, wasting your life away. Its better you are here instead of spreading your hate and idiocy in the real world. LMFAO!

    Hey Jack!!!

  • http://lifetechcapital.com/ltc/2014/06/fluoropharma-fpmi-update-06-03-14/

  • FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO

    8:34 AM ET 5/29/14 | Marketwire

    FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue 18F-FCPHA will be presented by the principal investigator, Olivier Gheysens, MD, PhD, at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

    The study was conducted at the University Hospital Leuven, Belgium. Collaborators on this study include Olivier Gheysens, MD, PhD, Andrey Postnov, PhD, Johan Nuyts, PhD, Koen Van Laere, MD, PhD, DrSc (Department of Nuclear Medicine & Molecular Imaging, University Hospital Leuven, Belgium), Stefan Janssens, MD, PhD (Department of Cardiology, University Hospital Leuven, Belgium) and Manuel Cerqueira, MD (Department of Nuclear Medicine, Cleveland Clinic, Cleveland, Ohio USA.)

  • Reply to

    Stock is on a tear....

    by fleipeg Apr 8, 2014 10:18 AM
    mulletman99 mulletman99 Apr 9, 2014 4:29 PM Flag

    Crazy, and we STILL only have a market cap of $25mil. Considering there are two products in phase 2 with potential revenue streams of $500 mil EACH, its got a LONG way to go to fair value, IMO.

PYMXQ
0.02010.0000(0.00%)Aug 27 11:02 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.